The novel metastasis promoter Merm1/Wbscr22 enhances tumor cell survival in the vasculature by suppressing Zac1/p53-dependent apoptosis

Cancer Research

Volumn 71, Issue 3, 2011, Pages 1146-1155

  Nakazawa, Youya ^a   Arai, Hiroyuki ^a   Fujita, Naoya ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE REPRESSION; HISTONE METHYLATION; METASTASIS; METASTASIS RELATED METHYLTRANSFERASE 1 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; WILLIAMS BEUREN SYNDROME CHROMOSOMAL REGION 22; ZAC1 GENE;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; ENDOTHELIAL CELLS; FEMALE; GENES, TUMOR SUPPRESSOR; HISTONES; MELANOMA, EXPERIMENTAL; METHYLTRANSFERASES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79551553123     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2695     Document Type: Article

References (40)

1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
3. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-20-deoxyuridine. J Natl Cancer Inst 1970;45:773-82.
4. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
5. Brown DM, Ruoslahti E. Metahedrin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004;5:365-74.
6. Pober BR. Williams-Beuren syndrome. N Engl J Med 2010;362:239-52.
7. Merla G, Ucla C, Guipponi M, Reymond A. Identification of additional transcripts in the Williams-Beuren syndrome critical region. Hum Genet 2002;110:429-38.
8. Daniel JA, Pray-Grant MG, Grant PA. Effector proteins for methylated histones: an expanding family. Cell Cycle 2005;4:919-26.
9. Li X, Zhao X. Epigenetic regulation of mammalian stem cells. Stem Cells Dev 2008;17:1043-52.
10. Kim JY, Kee HJ, Choe NW, Kim SM, Eom GH, Baek HJ, et al. Multiple-myeloma- related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol 2008;28:2023-34.
11. Gao SB, Feng ZJ, Xu B, Wu Y, Yin P, Yang Y, et al. Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. Oncogene 2009;28:4095-104.
12. Yang YJ, Han JW, Youn HD, Cho EJ. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res 2010;38:382-90.
13. Huang SM, Schonthal AH, Stallcup MR. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene 2001;20:2134-43.
14. Varrault A, Ciani E, Apiou F, Bilanges B, Hoffmann A, Pantaloni C, et al. hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. Proc Natl Acad Sci U S A 1998;95:8835-40.
15. Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, Pantaloni C, et al. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 1999;18:3979-88. (Pubitemid 29361336)
16. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525-28.
17. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001;61:333-8.
18. Zhang L, Hill RP. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 2004;64:4180-9.
19. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6:449-58.
20. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, et al. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 1991;51:5800-5.
21. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, et al. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995;10:869-79.
22. Ko J, Shin SM, Oh YM, Lee YS, Ryoo ZY, Lee YH, et al. Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice. Oncogene 2004;23:1950-3.
23. Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA, Varmus HE. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 2005;25:1228-37.
24. Tsuruo T, Yamori T, Naganuma K, Tsukagoshi S, Sakurai Y. Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Res 1983;43:5437-42.
25. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-79.
26. Hendrix MJ, Wood WR, Seftor EA, Lotan D, Nakajima M, Misiorowski RL, et al. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 1990;50:4121-30.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
28. Martin JL, McMillan FM. SAM (dependent) I AM: the S-adenosylmethionine- dependent methyltransferase fold. Curr Opin Struct Biol 2002;12:783-93.
29. Kozbial PZ, Mushegian AR. Natural history of S-adenosylmethionine-binding proteins. BMC Struct Biol 2005;5:19.
30. Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res 2009;7:557-69.
31. Tsuruo T, Yamori T, Naganuma K, Hori K, Kawabata H, Tsukagoshi S, et al. Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. Gann 1984;75:193-8.
32. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998;76:418-22.
33. Takebayashi S, Tamura T, Matsuoka C, Okano M. Major and essential role for the DNA methylation mark in mouse embryogenesis and stable association of DNMT1 with newly replicated regions. Mol Cell Biol 2007;27:8243-58.
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
35. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
36. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A 1987;84:7716-19.
37. Lee H, Larner JM, Hamlin JL. Cloning and characterization of Chinese hamster p53 cDNA. Gene 1997;184:177-83.
38. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
39. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46.
40. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.